LION BIOTECHNOLOGIES, INC. (NASDAQ:LBIO) Files An 8-K Entry into a Material Definitive Agreement

LION BIOTECHNOLOGIES, INC. (NASDAQ:LBIO) Files An 8-K Entry into a Material Definitive Agreement

Story continues below

Item 1.01.

Entry into a Material Definitive Agreement.

On April 28, 2017, Lion Biotechnologies, Inc. (the Company)
entered into a sublease agreement (the Sublease) with Teradata
US, Inc., which remains subject to the consent of the landlord,
to which the Company agreed to sublease certain office space
located adjacent to the Company’s headquarters in San Carlos,
California. The Sublease provides for additional space needed to
accommodate the recent growth of the Company. The space consists
of approximately 11,449 rentable square feet in the building
located at 999 Skyway Landing Road, San Carlos, California 94070.
This additional subleased space will be used by the Company for
administrative and other corporate purposes. The term of the
Sublease will commence ten days after the landlord consents in
writing to the Sublease, and will expire on October 31, 2018.

The preceding summary does not purport to be complete and is
qualified in its entirety by reference to the Sublease, which is
filed as Exhibit 10.1, and which is incorporated herein by

Item 2.02. Results of Operations and Financial

On May 1, 2017, the Company issued a press release announcing its
financial results for the first quarter ended March 31, 2017 and
an update on recent developments. A copy of that press release is
furnished as Exhibit 99.1 and is incorporated by reference

The information furnished under this Item 2.02, including the
accompanying Exhibit 99.1, shall not be deemed to be filed for
the purposes of Section 18 of the Securities Exchange Act of 1934
(the Exchange Act), or otherwise subject to the liability of such
section, nor shall such information be deemed to be incorporated
by reference in any subsequent filing by the Company under the
Securities Act of 1933 or the Exchange Act, regardless of the
general incorporation language of such filing, except as
specifically stated in such filing.

Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
Exhibit No. Description
10.1 Sublease Agreement, entered into as of April 28, 2017,
between Lion Biotechnologies, Inc. and Teradata US, Inc.
99.1 Press Release of Lion Biotechnologies, Inc., dated May 1,


Lion Biotechnologies, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead pipeline candidate, LN-144, is an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) to treat patients with refractory metastatic melanoma. The Company develops a portfolio of TIL-based products for the treatment of solid tumors. In addition to LN-144, the Company intends to develop additional TIL-based pipeline products to treat a range of solid tumors. It develops LN-145 to treat cervical and head and neck cancers. TIL therapy involves growing a patient’s TIL in special culture conditions outside the patient’s body, or ex vivo, and then infusing the T cells back into the patient in combination with interleukin-2 (IL-2).


LION BIOTECHNOLOGIES, INC. (NASDAQ:LBIO) closed its last trading session up +0.05 at 6.90 with 185,599 shares trading hands.

An ad to help with our costs